Participants 137 172 4
patients undergoing cardiac surgery
Participants 710 1018 4
Phase 3, prospective, randomized, double-blind, multicenter study to compare TISSEEL VH S/D to TISSEEL VH during cardiac surgery. The primary efficacy endpoint was the proportion of patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure.
Participants 1760 1810 4
hemostasis in patients undergoing cardiac surgery.
